Trial · NCT01709227
Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
NCT01709227, Not applicable, Completed, Children's Hospital Medical Center, Cincinnati; results first posted 2017-06-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass. Trials, record NCT01709227. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01709227
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
- NCT number
- NCT01709227
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 73 participants, actual
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Conditions
- Acute Kidney Injury
- Interventions
- Furosemide, Peritoneal Dialysis
- First posted
- 2012-10-18
- Last updated
- 2017-06-09
- Results first posted
- 2017-06-09
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Negative Fluid Balance on Postop Day 1 | Postop day 1 | Difference of inputs and outputs, including urine output and PD drainage. |
| Secondary | Respiratory Support Administered | Duration of postoperative intubation (average time approximately- 1 week) | Duration of initial course of postoperative mechanical ventilation |
| Secondary | NGAL Concentration | Pre-op, and postop (2hr, 6hr, 12hr, 24hr, 48hr) | |
| Secondary | Duration of Cardiac ICU Stay | Average 2 weeks | Total days of initial postoperative stay in cardiac ICU |
| Secondary | Duration of Hospital Stay | Average 4 weeks | Total days of initial postoperative stay in hospital |
| Secondary | All Cause Mortality | duration of hospitalization (an average of 2 weeks) | In-hospital mortality |
| Secondary | Renal/Electrolyte Abnormalities | Postop morning 1-5 | Total sum of renal and electrolyte abnormalities over the first 5 postoperative days as defined in the protocol |
| Secondary | Doses of Potassium Chloride or Arginine Chloride Required | Postop day 0-5 | Total doses of potassium chloride or arginine chloride given during the first five postoperative days. |
| Secondary | B-Natriuretic Peptide | At 24hours and 48 hours postoperative | BNP measured at 24 and 48 hours postoperatively |
| Secondary | Modified Oxygenation Index | at 24 and 48 hours postoperative | Product of Mean airway pressure delivered by mechanical ventilation and FiO2 of administered oxygen |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Negative Fluid Balance on Postop Day 1 | Postop day 1 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Respiratory Support Administered | Duration of postoperative intubation (average time approximately- 1 week) | days | MEDIAN | |
| SECONDARY | NGAL Concentration | Pre-op, and postop (2hr, 6hr, 12hr, 24hr, 48hr) | Data were collected but not analyzed. Due to a high incidence of volatile and un-reportable NGAL levels, concerns were raised about the storage or processing of samples affecting data validity. Given the overwhelming concern of erroneous data, analysis was not performed as planned. | ||
| SECONDARY | Duration of Cardiac ICU Stay | Average 2 weeks | days | MEDIAN | |
| SECONDARY | Duration of Hospital Stay | Average 4 weeks | days | MEDIAN | |
| SECONDARY | All Cause Mortality | duration of hospitalization (an average of 2 weeks) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Renal/Electrolyte Abnormalities | Postop morning 1-5 | abnormalities | MEDIAN | |
| SECONDARY | Doses of Potassium Chloride or Arginine Chloride Required | Postop day 0-5 | doses given | MEDIAN | |
| SECONDARY | B-Natriuretic Peptide | At 24hours and 48 hours postoperative | pg/ml | MEAN | |
| SECONDARY | Modified Oxygenation Index | at 24 and 48 hours postoperative | Units | MEDIAN |
Source ClinicalTrials.gov
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Negative Fluid Balance on Postop Day 1 | Furosemide | 21 | Participants | ||
| Number of Participants With Negative Fluid Balance on Postop Day 1 | Peritoneal Dialysis | 29 | Participants | ||
| Respiratory Support Administered | Furosemide | 4 | Inter-Quartile Range 2 to 6 | days | |
| Respiratory Support Administered | Peritoneal Dialysis | 3 | Inter-Quartile Range 2 to 4 | days | |
| Duration of Cardiac ICU Stay | Furosemide | 9 | Inter-Quartile Range 5 to 15 | days | |
| Duration of Cardiac ICU Stay | Peritoneal Dialysis | 7 | Inter-Quartile Range 6 to 12 | days | |
| Duration of Hospital Stay | Furosemide | 15 | Inter-Quartile Range 10 to 28 | days | |
| Duration of Hospital Stay | Peritoneal Dialysis | 14 | Inter-Quartile Range 9 to 22 | days | |
| All Cause Mortality | Furosemide | 3 | Participants | ||
| All Cause Mortality | Peritoneal Dialysis | 1 | Participants |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Furosemide | 32 | |
| Overall Study | STARTED | Peritoneal Dialysis | 41 | |
| Overall Study | COMPLETED | Furosemide | 31 | |
| Overall Study | COMPLETED | Peritoneal Dialysis | 32 | |
| Overall Study | NOT COMPLETED | Furosemide | 1 | |
| Overall Study | NOT COMPLETED | Peritoneal Dialysis | 9 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bleeding Event | Blood and lymphatic system disorders | Furosemide | 0 | 32 | 0 |
| other | Bleeding Event | Blood and lymphatic system disorders | Peritoneal Dialysis | 1 | 41 | 1 |
| other | Hydrocele | Skin and subcutaneous tissue disorders | Furosemide | 0 | 32 | 0 |
| other | Hydrocele | Skin and subcutaneous tissue disorders | Peritoneal Dialysis | 1 | 41 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Furosemide | 3 | 32 |
| Total, all-cause mortality | Peritoneal Dialysis | 1 | 41 |
| Total, other adverse events | Furosemide | 0 | 32 |
| Total, other adverse events | Peritoneal Dialysis | 2 | 41 |
| Total, serious adverse events | Furosemide | 0 | 32 |
| Total, serious adverse events | Peritoneal Dialysis | 0 | 41 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28241247 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Furosemide vs Peritoneal Dialysis: All Cause Mortality | Trial comparisons |
| Furosemide vs Peritoneal Dialysis: Number of Participants With Negative Fluid Balance on Postop Day 1 | Trial comparisons |
| Furosemide vs Peritoneal Dialysis: deaths from any cause | Trial comparisons |
| Furosemide vs Peritoneal Dialysis: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01709227
GET https://conductscience.org/api/trials/v1/NCT01709227/results?page=2